John Hollingsworth, MD
Pulmonary Disease · Fort Worth, TXNPI 1619051778
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.9%), education and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Intuitive Surgical at 53.3% of the total. Reporting peaked in 2020 at $3,514 and has fallen 93.4% since, to $233 in 2025.
Across 215 payments — averaging $40.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- GSK$597
- AstraZeneca$374
- Mylan Specialty L.p.$263
- Sanofi$260
- Actelion Pharmaceuticals US, Inc.$196
- plus $2K from 35 others
Across 59 payments — averaging $2159.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$127K
What the payments were for
- Travel & lodging$1,12113%
- Food & beverage$4,65153%
- Education$3,01234%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 17 | $4,678 |
| GSK | 32 | $597 |
| AstraZeneca | 23 | $374 |
| Mylan Specialty L.p. | 14 | $263 |
| Sanofi | 15 | $260 |
| Actelion Pharmaceuticals US, Inc. | 7 | $196 |
| Insmed, Inc. | 5 | $192 |
| Boehringer Ingelheim | 9 | $179 |
| Medivance, Inc. | 2 | $179 |
| Inari Medical, Inc. | 1 | $169 |
| Pulmonx Corporation | 5 | $163 |
| United Therapeutics Corporation | 6 | $135 |
| Abiomed | 3 | $134 |
| Merck | 8 | $132 |
| Novartis | 6 | $110 |
| Baxter Healthcare | 5 | $103 |
| Sunovion Pharmaceuticals Inc. | 16 | $96 |
| Gilead | 4 | $74 |
| Shionogi Inc | 3 | $68 |
| Amgen | 3 | $58 |
| AbbVie(2 entities) | 3 | $57 |
| Jazz Pharmaceuticals Inc. | 2 | $54 |
| Johnson & Johnson(2 entities) | 3 | $50 |
| Lundbeck LLC | 2 | $47 |
| La Jolla Pharmaceutical Company | 2 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Covis Pharma GmbH | 2 | $41 |
| Potrero Medical, Inc. | 1 | $33 |
| Mallinckrodt Enterprises LLC | 1 | $33 |
| Shire North American Group Inc | 2 | $33 |
| Body Vision Medical Inc. | 1 | $25 |
| Portola Pharmaceuticals, LLC | 1 | $23 |
| Inogen, Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Grifols USA, LLC | 1 | $14 |
| Harmony Biosciences LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Livanova USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,783 in reported general payments places this provider in the 75th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 12 | $154,653 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $70,297 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 46 | $33,569 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $22,697 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $10,911 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $5,113 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $2,681 |
| Roflumilast | 16 | $1,742 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 59 | $975 |
| Montelukast Sodium | 20 | $347 |
| Prednisone | 21 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $196 | $154,65312 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $597 | $126,563141 claims |
| Boehringer IngelheimCombivent Respimat | $179 | $10,91116 claims |
| AstraZenecaSymbicort | $374 | $5,11314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Fort Worth
- Steven KimFort Worth$160K
- Andrew MillerFort Worth$112K
- David OstranskyFort Worth$107K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.